IGC Pharma Inc (IGC)

Name: IGC Pharma Inc Financial Statements
Creator: Quarter Results

Healthcare | Biotechnology

Latest reporting period: 2025-12-31

Latest Quarter

2025-12-31

Revenue

$350K

Net Income

-$726K

Operating Margin

-840.3%

Free Cash Flow

-$5.3M

Debt / Assets

27.6%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for IGC Pharma Inc (IGC).
Income Statement (Quarterly)	2025-12-31	2025-09-30	2025-06-30	2024-12-31
Revenue	350,000	191,000	328,000	257,000
Cost of Revenue	356,000	92,000	174,000	153,000
Gross Profit	-6,000	99,000	154,000	104,000
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	1,453,000	1,410,000	1,208,000	1,130,000
Operating Expenses	2,935,000	2,998,000	2,059,000	1,982,000
Operating Income	-2,941,000	-2,899,000	-1,905,000	-1,878,000
Interest Expense	0	0	0	0
Income Before Tax	-726,000	-1,821,000	-1,599,000	-1,829,000
Income Tax Expense	0	0	0	0
Net Income	-726,000	-1,821,000	-1,599,000	-1,829,000
Per Share
EPS	-0.01	-0.02	-0.02	-0.02
EPS Diluted	0.00	0.00	0.00	0.00

Income statement annual history for IGC Pharma Inc (IGC).
Income Statement (Annual)	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31
Revenue	1,271,000	1,345,000	911,000	397,000	898,000
Cost of Revenue	652,000	612,000	469,000	203,000	785,000
Gross Profit	619,000	733,000	442,000	194,000	113,000
Operating Expenses
R&D Expenses	0	0	0	0	0
SG&A Expenses	4,410,000	6,758,000	8,552,000	13,292,000	7,908,000
Operating Expenses	8,065,000	10,531,000	12,013,000	15,622,000	8,837,000
Operating Income	-7,446,000	-9,798,000	-11,571,000	-15,428,000	-8,724,000
Interest Expense	0	0	0	-412,000	0
Income Before Tax	-7,121,000	-13,000,000	-11,506,000	-15,016,000	-8,811,000
Income Tax Expense	0	0	-65,000	-412,000	0
Net Income	-7,121,000	-13,000,000	-11,506,000	-14,604,000	-8,811,000
Per Share
EPS	-0.09	-0.22	-0.22	-0.29	-0.21
EPS Diluted	0.00	0.00	0.00	0.00	0.00

Balance sheet quarterly history for IGC Pharma Inc (IGC).
Balance Sheet (Quarterly)	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Assets
Cash and Cash Equivalents	405,000	1,198,000	3,196,000	10,460,000
Short Term Investments	0	0	154,000	0
Net Receivables	77,000	39,000	131,000	597,000
Inventory	1,360,000	1,540,000	2,651,000	3,548,000
Total Current Assets	2,896,000	3,705,000	6,466,000	15,111,000
Property Plant Equipment	3,318,000	3,893,000	8,539,000	9,870,000
Goodwill and Intangibles	1,852,000	1,616,000	1,170,000	917,000
Total Assets	8,747,000	9,902,000	17,178,000	26,834,000
Liabilities
Account Payables	883,000	773,000	530,000	981,000
Short Term Debt	94,000	124,000	133,000	3,000
Total Current Liabilities	2,257,000	2,340,000	1,898,000	2,441,000
Long Term Debt	144,000	221,000	348,000	485,000
Total Liabilities	2,417,000	2,581,000	2,267,000	2,942,000
Shareholders Equity
Retained Earnings	-120,744,000	-113,665,000	-100,665,000	-89,159,000
Total Shareholders Equity	6,330,000	7,321,000	14,911,000	23,892,000

Balance sheet annual history for IGC Pharma Inc (IGC).
Balance Sheet (Annual)	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31
Assets
Cash and Cash Equivalents	405,000	1,198,000	3,196,000	10,460,000	14,548,000
Short Term Investments	0	0	154,000	0	80,000
Net Receivables	77,000	39,000	131,000	597,000	1,916,000
Inventory	1,360,000	1,540,000	2,651,000	3,548,000	5,478,000
Total Current Assets	2,896,000	3,705,000	6,466,000	15,111,000	23,517,000
Property Plant Equipment	3,318,000	3,893,000	8,539,000	9,870,000	11,328,000
Goodwill and Intangibles	1,852,000	1,616,000	1,170,000	917,000	407,000
Total Assets	8,747,000	9,902,000	17,178,000	26,834,000	35,867,000
Liabilities
Account Payables	883,000	773,000	530,000	981,000	476,000
Short Term Debt	94,000	124,000	133,000	3,000	304,000
Total Current Liabilities	2,257,000	2,340,000	1,898,000	2,441,000	2,368,000
Long Term Debt	144,000	221,000	348,000	485,000	681,000
Total Liabilities	2,417,000	2,581,000	2,267,000	2,942,000	3,064,000
Shareholders Equity
Retained Earnings	-120,744,000	-113,665,000	-100,665,000	-89,159,000	-74,143,000
Total Shareholders Equity	6,330,000	7,321,000	14,911,000	23,892,000	32,803,000

Cash flow quarterly history for IGC Pharma Inc (IGC).
Cash Flow Statement (Quarterly)	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Operating Activities
Net Income	-7,121,000	-13,000,000	-11,506,000	-15,016,000
Depreciation & Amortization	618,000	637,000	657,000	651,000
Stock Based Compensation	1,640,000	1,773,000	2,843,000	2,197,000
Change in Working Capital	-72,000	1,894,000	794,000	2,536,000
Operating Cash Flow	-4,795,000	-5,199,000	-7,047,000	-7,462,000
Investing Activities
Capital Expenditure	-482,000	-515,000	-619,000	-742,000
Investments	-112,000	-138,000	-619,000	-742,000
Investing Cash Flow	-442,000	-317,000	-235,000	-742,000
Financing Activities
Debt Repayment	-3,000	-3,000	-3,000	-3,000
Common Stock Issued/Repurchased	4,454,000	3,527,000	103,000	4,145,000
Dividends Paid	0	0	0	0
Financing Cash Flow	4,451,000	3,524,000	100,000	4,142,000
Summary
Free Cash Flow	-5,277,000	-5,714,000	-7,666,000	-8,204,000
Net Change in Cash	-793,000	-1,998,000	-7,264,000	-4,088,000

Cash flow annual history for IGC Pharma Inc (IGC).
Cash Flow Statement (Annual)	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31
Operating Activities
Net Income	-7,121,000	-13,000,000	-11,506,000	-15,016,000	-8,811,000
Depreciation & Amortization	618,000	637,000	657,000	651,000	478,000
Stock Based Compensation	1,640,000	1,773,000	2,843,000	2,197,000	658,000
Change in Working Capital	-72,000	1,894,000	794,000	2,536,000	-3,294,000
Operating Cash Flow	-4,795,000	-5,199,000	-7,047,000	-7,462,000	-10,800,000
Investing Activities
Capital Expenditure	-482,000	-515,000	-619,000	-742,000	-1,592,000
Investments	-112,000	-138,000	-619,000	-742,000	-1,470,000
Investing Cash Flow	-442,000	-317,000	-235,000	-742,000	3,387,000
Financing Activities
Debt Repayment	-3,000	-3,000	-3,000	-3,000	-50,000
Common Stock Issued/Repurchased	4,454,000	3,527,000	103,000	4,145,000	14,158,000
Dividends Paid	0	0	0	0	0
Financing Cash Flow	4,451,000	3,524,000	100,000	4,142,000	14,688,000
Summary
Free Cash Flow	-5,277,000	-5,714,000	-7,666,000	-8,204,000	-12,392,000
Net Change in Cash	-793,000	-1,998,000	-7,264,000	-4,088,000	7,290,000